India’s top-ranked drug firm, Sun Pharmaceutical Industries Ltd., reported a 5% decline in net profits at INR14.72bn ($220m) for the third quarter ended December 2016, dragged down by muted growth in India and the US.
But management referred to “significant momentum” in the firm’s specialty products strategy, where it continues to shore up its business...